Argenx Se (ARGX) Operating Expenses (2016 - 2026)
Argenx Se's (ARGX) quarterly Operating Expenses came in at $2.9 billion in Q2 2026, up 276.7% YoY from $766.1 million in Q2 2025, and up 414.04% on a QoQ basis from -$919.0 million in Q1 2026.
Argenx Se (ARGX) Operating Expenses (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Operating Expenses data on file, last reported at $2.9 billion in Q2 2026.
- Quarterly Operating Expenses rose 276.7% year-over-year to $2.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 260.18% YoY) and the FY2025 annual result came in at $3.2 billion, up 40.49% from the prior year.
- Operating Expenses rose to $2.9 billion in Q2 2026, from -$919.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.9 billion in Q2 2026 to a low of -$954.5 million in Q4 2025.
- A 5-year average of -$178.7 million and a median of -$401.8 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses plunged 87.65% — and 2026, when it surged 276.7%.
- Tracing ARGX's Operating Expenses over 5 years: stood at -$296.5 million in 2022, then sank by 87.65% to -$556.5 million in 2023, then dropped by 18.28% to -$658.2 million in 2024, then sank by 45.03% to -$954.5 million in 2025, then surged by 402.34% to $2.9 billion in 2026.
- The last three Operating Expenses figures came in at $2.9 billion (Q2 2026), -$919.0 million (Q1 2026), and -$954.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.89 Bn |
| Mar 31, 2026 | -919.00 Mn |
| Dec 31, 2025 | -954.54 Mn |
| Sep 30, 2025 | 805.14 Mn |
| Jun 30, 2025 | 766.13 Mn |
| Mar 31, 2025 | -668.00 Mn |
| Dec 31, 2024 | -658.18 Mn |
| Sep 30, 2024 | -574.69 Mn |
| Jun 30, 2024 | -534.89 Mn |
| Mar 31, 2024 | -505.93 Mn |
| Dec 31, 2023 | -556.46 Mn |
| Sep 30, 2023 | -420.43 Mn |
| Jun 30, 2023 | -383.13 Mn |
| Mar 31, 2023 | -333.62 Mn |
| Dec 31, 2022 | -296.55 Mn |
| Sep 30, 2022 | -355.13 Mn |
| Jun 30, 2022 | -259.73 Mn |
| Mar 31, 2022 | -254.21 Mn |
| Dec 31, 2021 | -264.60 Mn |
| Sep 30, 2021 | -220.06 Mn |